drugset / Trial / NCT00793429

Safety Study of Prucalopride in Healthy Volunteers

NCT00793429

Phase 1 Completed Movetis

Summary

In this study healthy volunteers received increasing doses of prucalopride to study the tolerability and cardiac safety of prucalopride. The study hypothesis was that prucalopride at doses up to 10 mg has no clinically relevant effect on the cardiovascular safety in healthy volunteers.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Prucalopride Small molecule 6 mg
Subject Prucalopride Small molecule 8 mg
Subject Prucalopride Small molecule 10 mg

Indications

No indication recorded.